These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22537852)

  • 21. Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
    Miyazaki J; Hinotsu S; Ishizuka N; Naito S; Ozono S; Akaza H; Nishiyama H
    Jpn J Clin Oncol; 2013 Aug; 43(8):827-34. PubMed ID: 23858038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycotic Thoracic Aortic Aneurysm After Intravesical Bacillus Calmette-Guérin Treatment.
    Seastedt KP; Ahmad U; Lau C; Ruggeri-Weigel P; Tsang HC; Hartman BJ; Girardi LN
    Ann Thorac Surg; 2015 Jun; 99(6):2210-2. PubMed ID: 26046881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strategies for optimizing bacillus Calmette-Guérin.
    Shah JB; Kamat AM
    Urol Clin North Am; 2013 May; 40(2):211-8. PubMed ID: 23540779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An unexpected complication of bacillus Calmette-Guérin therapy.
    Yildiz H; Colin G; Lambert M
    Acta Clin Belg; 2014 Aug; 69(4):312. PubMed ID: 24846180
    [No Abstract]   [Full Text] [Related]  

  • 25. Bilateral parotid glands infection caused by Calmette-Guerin Bacillus after intravesical therapy for recurrent bladder cancer: a case report.
    Friedlander E; Martínez Pascual P; Montilla de Mora P; Scola Yurrita B
    Braz J Otorhinolaryngol; 2017; 83(6):726-729. PubMed ID: 26923828
    [No Abstract]   [Full Text] [Related]  

  • 26. Nephrogenic adenoma of the bladder after intravesical bacillus Calmette-Guérin treatment.
    Kilciler M; Tan O; Ozgök Y; Tahmaz L; Deveci S; Erduran D
    Urol Int; 2000; 64(4):229-32. PubMed ID: 10895092
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bladder and penile lesions with inguinal adenopathy after intravesical Bacillus Calmette-Guerin (BCG) treatment.
    Yates J; Stein B
    Urology; 2007 Dec; 70(6):1223.e15-7. PubMed ID: 18158061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Worsening of bullous pemphigoid following bacillus Calmette-Guérin treatment for bladder cancer.
    Johnson JL; West DA; Travers JB
    JAMA Dermatol; 2013 Feb; 149(2):248-9. PubMed ID: 23426500
    [No Abstract]   [Full Text] [Related]  

  • 29. Bacille Calmette-Guérin and ocular inflammations.
    Shah AN; Uppal GS; Tappin MJ
    Urology; 2011 Apr; 77(4):1014-5. PubMed ID: 21477740
    [No Abstract]   [Full Text] [Related]  

  • 30. [Polyarthritis secondary to intravesical BCG instillation, a case report].
    Rincón Mayans A; Zudaire Bergera JJ; Brugarolas Rosselló J; Saiz Sansi A; Rioja Zuazu J; Regojo Balboa JM
    Actas Urol Esp; 2007 Apr; 31(4):400-3. PubMed ID: 17633927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer.
    Robinson ARL; Radhakrishnan R; Horvath R; Pandey S
    Intern Med J; 2017 Jul; 47(7):820-823. PubMed ID: 28677313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients.
    Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G
    J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncommon adverse events of intravesical Bacillus Calmette-Guérin treatment: A report of three cases.
    Topuz B; Zor M; Yılmaz S; Kaya E
    Rev Esp Quimioter; 2021 Aug; 34(4):383-386. PubMed ID: 33956411
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of Ta and T1 intermediate or high risk bladder cancer with intravesical Bacillus Calmette-Guérin or mitomycin C].
    Pyrgidis N; Lackner J; Schneidewind L; Sokolakis I
    Urologe A; 2021 Feb; 60(2):234-237. PubMed ID: 33479803
    [No Abstract]   [Full Text] [Related]  

  • 35. Isolated renal tuberculosis following intravesical Bacillus Calmette-Guérin therapy for bladder cancer.
    Wada Y; Sugiyama Y; Kikukawa H; Kuwahara T; Takahashi W; Takamiya T; Ueda S
    Urol Int; 2004; 72(3):257-60. PubMed ID: 15084773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P
    J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCG immunotherapy--from pathophysiology to clinical practice.
    Tishler M; Shoenfeld Y
    Expert Opin Drug Saf; 2006 Mar; 5(2):225-9. PubMed ID: 16503744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ocular involvement following Bacillus Calmette-Guerin immunotherapy for bladder carcinoma.
    Cugati S; Gilhotra JS; Lake S; Gordon DL
    Clin Exp Ophthalmol; 2014 Jul; 42(5):494-5. PubMed ID: 24372891
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety and efficacy of intravesical bacillus Calmette-Guérin plus interferon α-2b therapy for nonmuscle invasive bladder cancer in patients with prosthetic devices.
    Rosevear HM; Lightfoot AJ; Nepple KG; O'Donnell MA
    J Urol; 2010 Nov; 184(5):1920-4. PubMed ID: 20846678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cryoglobulinemia vasculitis following intravesical instillations of bacillus Calmette-Guerin.
    Granel B; Serratrice J; Morange PE; Disdier P; Weiller PJ
    Clin Exp Rheumatol; 2004; 22(4):481-2. PubMed ID: 15301249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.